Further analysis showed that among the 879 participants who tested negative for IgM at baseline (i.e., no SARS-CoV-2 acute infection) but who developed immune responses following vaccination at the baseline, 13 (1.5%) were IgM seropositive on follow-up (breakthrough infections after vaccination). Here, CD40LG is linked to infection.